Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
Evan Y. Yu, Daniel P. Petrylak, Peter H. O’Donnell, Jae‐Lyun Lee, Michiel S. van der Heijden, Yohann Loriot, Mark N. Stein, Andrea Necchi, Takahiro Kojima, Michael R. Harrison, Se Hoon Park, David I. Quinn, Elisabeth I. Heath, Jonathan E. Rosenberg, Joyce Steinberg, Shang-Ying Liang, Janet Trowbridge, Mary S. Campbell, Bradley A. McGregor, Arjun Vasant Balar
Topics & Concepts
Urothelial carcinomaCisplatinMedicineOncologyInternal medicineCarcinomaPhases of clinical researchUrologyClinical trialChemotherapyCancerBladder cancerBladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesEsophageal Cancer Research and Treatment